Economic Toll of Heart Failure in the US: Forecasting the Impact of Heart Failure in the United States – A Policy Statement From the American Heart Association
Reporter: Aviva Lev-Ari, PhD, RN
- AHA Policy Statement
Forecasting the Impact of Heart Failure in the United States
A Policy Statement From the American Heart Association
-
Paul A. Heidenreich, MD, MS, FAHA, Chair,
- Nancy M. Albert, PhD, RN, FAHA,
- Larry A. Allen, MD, MHS,
- David A. Bluemke, MD, PhD, FAHA,
- Javed Butler, MD, MPH, FAHA,
- Gregg C. Fonarow, MD, FAHA,
- John S. Ikonomidis, MD, PhD, FRCS(C), FAHA,
- Olga Khavjou, MA,
- Marvin A. Konstam, MD,
- Thomas M. Maddox, MD, MSc,
- Graham Nichol, MD, MPH, FRCP(C), FAHA,
- Michael Pham, MD, MPH,
- Ileana L. Piña, MD, MPH, FAHA,
- Justin G. Trogdon, PhD and
- on behalf of the American Heart Association Advocacy Coordinating Committee:
- Council on Arteriosclerosis,
- Thrombosis and Vascular Biology,
- Council on Cardiovascular Radiology and Intervention,
- Council on Clinical Cardiology,
- Council on Epidemiology and Prevention, and
- Stroke Council
Abstract
Background—Heart failure (HF) is an important contributor to both the burden and cost of national healthcare expenditures, with more older Americans hospitalized for HF than for any other medical condition. With the aging of the population, the impact of HF is expected to increase substantially.
Methods and Results—We estimated future costs of HF by adapting a methodology developed by the American Heart Association to project the epidemiology and future costs of HF from 2012 to 2030 without double counting the costs attributed to comorbid conditions. The model assumes that HF prevalence will remain constant by age, sex, and race/ethnicity and that rising costs and technological innovation will continue at the same rate.
By 2030,
- >8 million people in the United States (1 in every 33) will have HF.
- Between 2012 and 2030, real (2010$) total direct medical costs of HF are projected to increase from $21 billion to $53 billion.
- Total costs, including indirect costs for HF, are estimated to increase from $31 billion in 2012 to $70 billion in 2030.
- If one assumes all costs of cardiac care for HF patients are attributable to HF (no cost attribution to comorbid conditions), the 2030 projected cost estimates of treating patients with HF will be 3-fold higher ($160 billion in direct costs).
Conclusions—The estimated prevalence and cost of care for HF will increase markedly because of aging of the population. Strategies to prevent HF and improve the efficiency of care are needed.
Key Words:
http://circheartfailure.ahajournals.org/content/early/2013/04/24/HHF.0b013e318291329a.abstract
15 page PDF, at the below link
REFERENCE
Four Policy Statement From the American Heart Association
-
AHA Policy StatementForecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association
- Paul A. Heidenreich,
- Nancy M. Albert,
- Larry A. Allen,
- David A. Bluemke,
- Javed Butler,
- Gregg C. Fonarow,
- John S. Ikonomidis,
- Olga Khavjou,
- Marvin A. Konstam,
- Thomas M. Maddox,
- Graham Nichol,
- Michael Pham,
- Ileana L. Piña,
- and Justin G. Trogdon
Circ Heart Fail. 2013;published online before print April 24 2013,doi:10.1161/HHF.0b013e318291329a
…American Heart Association. Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations…and improve the efficiency of care are needed. AHA Scientific Statements|heart failure| -
Select this article
Special ReportStatement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States
- Michael A. Acker,
- Francis D. Pagani,
- Wendy Gattis Stough,
- Douglas L. Mann,
- Mariell Jessup,
- Robert Kormos,
- Mark S. Slaughter,
- Timothy Baldwin,
- Lynne Stevenson,
- Keith D. Aaronson,
- Leslie Miller,
- David Naftel,
- Clyde Yancy,
- Joseph Rogers,
- Jeffrey Teuteberg,
- Randall C. Starling,
- Bartley Griffith,
- Steven Boyce,
- Stephen Westaby,
- Elizabeth Blume,
- Peter Wearden,
- Robert Higgins,
- and Michael Mack
Circ Heart Fail. 2013;6:e1-e11, published online before print November 12 2012,doi:10.1161/HHF.0b013e318279f6b5
…wolterskluwer.com . Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations…of Mechanically Assisted Circulatory Support.AHA Scientific Statements|heart-assist device|heart failure|BTC… -
Select this article
Special ReportStatement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States: Executive Summary
- Michael A. Acker,
- Francis D. Pagani,
- Wendy Gattis Stough,
- Douglas L. Mann,
- Mariell Jessup,
- Robert Kormos,
- Mark S. Slaughter,
- Timothy Baldwin,
- Lynne Stevenson,
- Keith D. Aaronson,
- Leslie Miller,
- David Naftel,
- Clyde Yancy,
- Joseph Rogers,
- Jeffrey Teuteberg,
- Randall C. Starling,
- Bartley Griffith,
- Steven Boyce,
- Stephen Westaby,
- Elizabeth Blume,
- Peter Wearden,
- Robert Higgins,
- and Michael Mack
Circ Heart Fail. 2013;6:145-150, published online before print November 12 2012,doi:10.1161/HHF.0b013e318279f55d
…wolterskluwer.com . Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations…of Mechanically Assisted Circulatory Support.AHA Scientific Statements|heart-assist device|heart failure| Background… -
Select this article
ACCF/AHA/HFSA Data and Survey ReportACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Support Device Implantation: A Report of the ACCF Heart Failure and Transplant Committee, AHA Heart Failure and Transplantation Committee, and Heart Failure Society of America
- Mariell Jessup,
- Nancy M. Albert,
- David E. Lanfear,
- JoAnn Lindenfeld,
- Barry M. Massie,
- Mary Norine Walsh,
- and Mark J. Zucker
Circ Heart Fail. 2011;4:378-387, published online before print April 4 2011,doi:10.1161/HHF.0b013e3182186210
…hired for a given practice volume. These survey results are an initial step in developing such standards. AHA Scientific Statements|heart failure|heart transplant|mechanical circulatory support device|staffing profile| 1. Introduction…
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette